An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD

This study has been completed.

First Received: April 15, 2003 Last Updated: August 4, 2008 History of Changes

Sponsor:	Alcon Research
Information provided by:	Alcon Research
ClinicalTrials.gov Identifier:	NCT00058994

Purpose

The purpose of this study is to demonstrate that anecortave acetate is superior to placebo in maintenance of visual acuity at the 12- and 24-month visits.

Condition	Intervention	Phase
Macular Degeneration Maculopathy, Age-Related	Drug: anecortave acetate	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal Choroidal Neovascularization Due to Exudative Age-Related Macular Degeneration

Resource links provided by NLM:

Genetics Home Reference related topics: X-linked juvenile retinoschisis

MedlinePlus related topics: Macular Degeneration

Drug Information available for: Anecortave acetate

U.S. FDA Resources

Further study details as provided by Alcon Research:

Study Start Date:	March 2003
Study Completion Date:	November 2006
Primary Completion Date:	November 2006 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	50 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Patients at least 50 years of age, of any race, and either sex with a clinical diagnosis of exudative AMD and a primary or recurrent subfoveal CNV lesion in the study eye.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00058994

Locations

United States, Texas
South America
Fort Worth, Texas, United States

Sponsors and Collaborators

Alcon Research

Investigators

Principal Investigator:

Alcon Investigators

Alcon Research

More Information

No publications provided

Study ID Numbers:	C-02-29
Study First Received:	April 15, 2003
Last Updated:	August 4, 2008
ClinicalTrials.gov Identifier:	NCT00058994 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Alcon Research:

AMD
anecortave acetate
wet AMD
age-related macular degeneration
Macular Degeneration

Maculopathy, Age-Related
Age-Related Maculopathies
Age-Related Maculopathy
Maculopathies, Age-Related

Additional relevant MeSH terms:

Uveal Diseases
Pathologic Processes
Metaplasia
Eye Diseases
Choroid Diseases

Retinal Degeneration
Macular Degeneration
Neovascularization, Pathologic
Retinal Diseases
Choroidal Neovascularization

ClinicalTrials.gov processed this record on November 09, 2009